News

New BIO Report Highlights Virginia’s Bioscience Industry Increases Jobs, NIH Awards and More

The Biotechnology Innovation Organization (BIO) released new data on the bioscience industry in the United States in their report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities. This report outlines the bioscience industry’s economic footprint across the nation and in Virginia, as well as the significant role played by small- and mid-sized companies. The report further analyzes the industry’s response to the COVID-19 pandemic, and more broadly highlights the importance of the bio-ecosystem in times of pandemic, which requires rapid response and innovation.

The report recognizes Virginia at the national level for steady growth of NIH research funding and specialized employment in the bioscience, agricultural feedstock, and pharmaceutical subsectors. At the Commonwealth level, the bioscience industry outperformed the private sector with increases in wages and establishments. Virginia also experienced steady increases across the board in the bioscience industry as shown below.

● $86,212 average annual wage
● 24,346 employees
● 2,058 establishments
● $854M bioscience-related R&D expenditures
● $506.1M total NIH funding

”The bioscience industry plays a critical role in Virginia of creating jobs, quality wages, and innovative technologies. Virginia Bio is proud to serve as an advocate to our members whose businesses and technologies feed this bio-ecosystem. Members, who are in our own backyards, are working on life-saving technologies and reaching national recognition for their accolades. This bio-ecosystem must be protected to ensure vitality of this industry and to maintain its role as an economic driver in Virginia,” said John Newby, CEO of Virginia Biotechnology Association.

The state-by-state industry assessment is the ninth in a biennial series, developed in partnership by TEConomy and BIO, and studies the state of the U.S. bioscience industry and its associated innovation ecosystem at the national, state, and metropolitan area levels.

The analysis includes a fact sheet for Virginia, which can be found via the interactive map at www.bio.org/jobs.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and